Prevention of Bleeding in Total Joint Replacement: Combined Route Administration of Tranexamic Acid

• Status: Completed
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The investigators aimed to compare two doses of intravenous (IV) tranexamic acid (TXA) with a combined single dose of topical and IV TXA on haemoglobin decline 24 hours after total joint arthroplasties.

The investigators conducted randomized, double-blind trial. The participants were randomized to either intrvenous group receiving 2 doses of 1 gram TXA in intravenous route 3 hours apart, or a combined application group receiving the first 1 gram IV and the topical dose was 1.5 gram after reduction of the fascia.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mongi Slim Hospital
• Treatments: Tranexamic Acid

Criteria

Inclusion Criteria:

• Patients aged of 18 years or more;

• Primary total hip or knee arthroplasty;

• A traumatic, degenerative or malformative setting.

Exclusion Criteria:

• Revisions;

• Bilateral procedures;

• Polytrauma;

• Pregnant patients;

• Contraindications for the use of TXA, Coagulation disorders or anaemia with Haemoglobin (Hb) less than or equal to 9 g/dl preoperatively;

• Patients treated with anticoagulants, Heparin, Warfarin, Oestrogen.

• Serious anaesthesia-related complications (impossible orotracheal intubation , anaphylactic shock);

• Severe transfusion reaction such as haemolysis.